Evidence map›Paper›PMID 30657254›Full record

ArticleMolecular oncology2019

TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.

Hui-Huang Lai, Chih-Wei Li, Chih-Chen Hong, Hung-Yu Sun, Ching-Feng Chiu, Da-Liang Ou, Pai-Sheng Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Hui-Huang LaiInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID 0000-0003-3594-3271
Chih-Wei LiDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chih-Chen HongInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
Hung-Yu SunDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ching-Feng ChiuGraduate Institute of Metabolism and Obesity Sciences, College of Nutrition, Taipei Medical University, Taiwan.
Da-Liang OuGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Pai-Sheng ChenInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
National Cheng Kung University · TWHunan University · CNNational Health Research Institutes · TWNational Taiwan University · TWTaipei Medical University · TW

Funding

Ministry of Science and Technology, Taiwan 105-2320-B-006-050Ministry of Science and Technology, Taiwan 106-2314-B-002-229-MY3Ministry of Science and Technology, Taiwan 106-2320-B-006-021Ministry of Science and Technology, Taiwan 106-2320-B-006-038Ministry of Science and Technology, Taiwan 107-2320-B-006-068
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer-related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor. The multikinase inhibitor sorafenib is the first-line treatment for patients with advanced HCC. However, cases of primary or acquired resistance to sorafenib have gradually increased, leading to a predicament in HCC therapy. Thus, it is critical to investigate the mechanism underlying sorafenib resistance. Transactivation response element RNA-binding protein 2 (TARBP2) is a multifaceted miRNA biogenesis factor that regulates cancer stem cell (CSC) properties. The tumorigenicity and drug resistance of cancer cells are often enhanced due to the acquisition of CSC features. However, the role of TARBP2 in sorafenib resistance in HCC remains unknown. Our results demonstrate that TARBP2 is significantly downregulated in sorafenib-resistant HCC cells. The TARBP2 protein was destabilized through autophagic-lysosomal proteolysis, thereby stabilizing the expression of the CSC marker protein Nanog, which facilitates sorafenib resistance in HCC cells. In summary, here we reveal a novel miRNA-independent role of TARBP2 in regulating sorafenib resistance in HCC cells.

Indexed as

Drug Resistance, NeoplasmAnimalsAutophagyCarcinoma, HepatocellularCell Line, TumorDown-RegulationGene Expression Regulation, NeoplasticHumansLiver NeoplasmsLysosomesMaleMice, Inbred BALB CMicroRNAsModels, BiologicalNanog Homeobox ProteinProtein StabilityMicroRNAsNanog Homeobox ProteinNANOG protein, humanRNA-Binding ProteinsSorafenibTrans-Activation Responsive RNA-Binding Proteincancer stem cellshepatocellular carcinomamiRNANanogsorafenib resistanceTARBP2

Identifiers

PMID30657254
PMCPMC6441883
OpenAlexW2910641602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.